FIELD: biotechnology.
SUBSTANCE: invention refers to a method for inducing the immune response on Neisseria meningitidis in a human subject aged 10 to 26 years. Method comprises administering to a human a composition comprising (a) a liquid composition comprising a first polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1, and a second polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2; and (b) a lyophilised composition containing the serogroup A, C, W and Y conjugated capsular saccharide Neisseria meningitides.
EFFECT: invention provides inducing the immune response on Neisseria meningitides in a human subject aged 10 to 26 years.
22 cl, 3 dwg, 25 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS FOR USING THEM | 2017 |
|
RU2739504C2 |
| COMPOSITIONS OF NEISSERIA MENINGITIDIS AND METHODS FOR PREPARATION THEREOF | 2016 |
|
RU2723045C2 |
| MODIFIED PROTEIN BINDING FACTOR H | 2017 |
|
RU2773464C1 |
| OPTIONS FOR H-BINDING PROTEIN FACTOR AND METHODS OF THEIR USE | 2015 |
|
RU2811942C2 |
| VERSIONS OF FACTOR N-BINDING PROTEIN AND METHODS OF USE THEREOF | 2015 |
|
RU2714248C2 |
| FMDV RECOMBINANT VACCINES AND USE THEREOF | 2015 |
|
RU2745373C2 |
| MESSENGER RNA VACCINES AGAINST WIDE RANGE OF CORONAVIRUS VARIANTS | 2022 |
|
RU2826172C2 |
| FIMH ESCHERICHIA COLI MUTANTS AND USE THEREOF | 2021 |
|
RU2831010C1 |
| SELF-ASSEMBLED NANOSTRUCTURED VACCINES | 2019 |
|
RU2811439C2 |
| ANTIGENS AND ANTIGEN COMPOSITIONS | 2013 |
|
RU2727476C2 |
